/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
For years, Cipla has helped drive India’s rise as the pharmacy of the world. Today, the drugmaker has a problem most would kill for. It is sitting on around Rs 9,500 crore, or almost $1 billion, in net cash and has one of the strongest balance sheets in India’s pharmaceutical industry. Yet, Cipla has made sure the cash remains unused, even as nearly every other peer has spent the last two years shipping, licensing and launching its way into pharma's next decade.
On its earnings call for the first quarter of 2026-27 last week, Cipla explained its restraint. “On the …
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
